Gene therapy for haemophilia: an update on progress in clinical trials

1. Cancio MI, Reiss UM, Nathwani AC, et al. Developments in the treatment of hemophilia B: focus on emerging gene therapy. Appl Clin Genet 2013; 6: 91-101. doi: 10.2147/TACG.S31928.Search in Google Scholar

2. Gringeri A, Ewenstein B, Reininger A. The burden of bleeding in haemophilia: is one bleed too many? Haemophilia 2014; 20(4): 459-63. doi: 10.1111/hae.12375.Search in Google Scholar

3. Schrijvers LH, Uitslager N, Schuurmans MJ, Fischer K.Barriers and motivators of adherence to prophylactic treatment in haemophilia: a systematic review. Haemophilia 2013 5; 19(3): 355-6. doi: 10.1111/hae.12079.Search in Google Scholar

4. Kaufman RJ, Powell JS. Molecular approaches for improved clotting factors for haemophilia. Hematology Am Soc Hematol Educ Program 2013; 2013: 30-6. doi: 10.1182/asheducation-2013.1.30.Search in Google Scholar

5. Chuah MK, Evens H, VandenDriessche T. Gene therapy for hemophilia. J Thromb Haemost 2013; 11 Suppl 1: 99-110. doi: 10.1111/jth.12215.Search in Google Scholar

6. Porada CD, Stem C, Almeida-Porada G. Gene Therapy; The promise of a permanent cure. N C Med J 2013; 74(6): 526-9.10.18043/ncm.74.6.526Search in Google Scholar

7. Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 1999; 5(1): 64-70.10.1038/47519883841Open DOISearch in Google Scholar

8. Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 2002; 99(8): 2670-6.10.1182/blood.V99.8.267011929752Search in Google Scholar

9. High KA. The gene therapy journey for hemophilia: are we there yet? Blood 2012; 120(23): 4482-7. doi: 10.1182/blood-2012-05-423210.Search in Google Scholar

10. Mingozzi F, High KA. Immune responses to AAV vectors: overcoming barriers to successful gene therapy Blood 2013; 122(1): 23-36. doi: 10.1182/blood-2013-01-306647.Search in Google Scholar

11. Roth DA, Tawa NE, O’Brien JM, et al. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe haemophilia A. N Engl J Med 2001; 344(23): 1735-1742.10.1056/NEJM20010607344230111396439Search in Google Scholar

12. Powell JS, Ragni MV, White GC, et al. Phase 1 trial of FVIII gene transfer for severe haemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 2003; 102(6): 2038-2045.10.1182/blood-2003-01-016712763932Search in Google Scholar

13. White GC, Monahan PE. Gene therapy for haemophilia A. In: Lee CA, Berntorp EE, Hoots K, editors. Textbook of Haemophilia. 2nd ed. Hoboken, NJ: Wiley- Blackwell; 2005.Search in Google Scholar

14. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe haemophilia B. Blood 2003; 101(8): 2963- 297210.1182/blood-2002-10-329612515715Search in Google Scholar

15. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in haemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006; 12(3): 342-347.10.1038/nm135816474400Open DOISearch in Google Scholar

16. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365: 2357-65. doi: 10.1056/NEJMoa1108046.Search in Google Scholar

17. Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371: 1994-2004. doi: 10.1056/NEJMoa1407309.Search in Google Scholar

18. http://www.fda.gov/22735246Search in Google Scholar

19. Pick A, Gilbert K, McCaul J. The role of effective communication in achieving informed consent for clinical trials. Nurs Stand 2014 Nov 5;29(10):45-8. doi: 10.7748/ns.29.10.45.e9443.Search in Google Scholar